ArticleEye (London, England)2025
Clinical features, treatment, and prognosis of zoledronic acid-induced uveitis.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database.Endocrine connections · 2025Article
- Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications.Clinical optometry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUveitis is a rare ocular adverse reaction of zoledronic acid, the specific clinical features are not clarified. This study was to investigate the clinical features of zoledronic acid-induced uveitis and provide reference for rational use of zoledronic acid.
methodsWe collected clinical data on zoledronic acid-induced uveitis for retrospective analysis by searching Chinese and English data up to October 31, 2024.
resultsUveitis occurred in 44 patients with a median age of 66.5 years (range 47, 87) and 93.2% in females. The median time to onset of uveitis was 48 h (range 10, 192). Eye pain (86.4%), decreased vision (61.4%), and redness (50.0%) were the most commonly described symptoms. Uveitis could involve unilateral eyes (68.2%) and bilateral eyes (31.8%), and anterior uveitis was the main type (95.5%). Most patients had intraocular pressure within the normal range. Slit lamp examination mainly revealed cells (54.5%), flare (43.2%), and keratic precipitates (29.5%). After discontinuation of zoledronic acid (97.6%) and receipt of topical steroids (97.7%), systemic steroids (15.9%), and cycloplegics (72.7%), all patients showed improvement or recovery.
conclusionZoledronic acid-induced uveitis mainly occurs within 72 h after the initial administration, and anterior uveitis is predominant. When zoledronic acid is used, patients should be informed of possible adverse eye reactions. Topical corticosteroids can be used as the main treatment for uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.